A Novel Nuclear-Localized Micropeptide, MP60, Promotes Hepatocellular Carcinoma Progression via the Epithelial-Mesenchymal Transition
Cancers · 07.09.2025 · 17 (17) · 2932
DOI: 10.3390/cancers17172932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 07.09.2025. Verfasst von Chencheng Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Province Engineering Research Center of Synthetic Peptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing 210009, Chi…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, University-Industry Collaboration Program, National Key R&D Program of China.
Abstract (Originalsprache)
Background
Micropeptides, encoded by non-coding RNAs, play a pivotal role in various cellular functions. While several micropeptides have already been linked to HCC, their roles remain incompletely understood. Our study identifies MP60, a conserved micropeptide strongly associated with HCC progression. Methods and Results: By analyzing The Cancer Genome Atlas (TCGA) dataset, we assessed the coding potential of long non-coding RNAs (lncRNAs) with significant expression changes in HCC. Our findings reveal that ENST0000614292, a transcript of LINC01138, exhibited the highest coding potential, encoding a putative 60-amino-acid micropeptide, which we have named MP60 and confirmed the expression of MP60 in HCC tissues, with a nuclear localization. MP60 directly interacts with RNA-binding motif protein 10 (RBM10) and downregulates its expression. Additionally, MP60 modulates EMT. Functional analyses demonstrated that MP60 promotes cellular proliferation and migration, while reducing cellular adhesion, translated by enhanced tumorigenesis in vivo. Notably, MP60 expression is markedly increased in HCC tissues and is associated with a poorer prognosis.
Conclusions
These findings identify MP60 as a potential biomarker and therapeutic target in HCC, linking its oncogenic effects to EMT modulation and tumor progression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Province Engineering Research Center of Synthetic Peptide Drug Discovery and Evaluation, China Pharmaceutical University, Nanjing 210009, China.
- Nanjing Anji Biotechnology Co., Ltd., Nanjing 210033, China.
- State Key Laboratory of Natural Medicines, Ministry of Education, China Pharmaceutical University, Nanjing 210009, China.
Förderung
- National Natural Science Foundation of China
- University-Industry Collaboration Program
- National Key R&D Program of China
- Natural Science Foundation of Jiangsu Province
- National Key R&D Program of China
- Open Project of the State Key Laboratory of Natural Medicines
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- ‘Double First-Class’ University project
Zitieren
APA
Li, C., Hong, X., Setrerrahmane, S., Sun, X., Zhang, X., & Xu, H. (2025). A Novel Nuclear-Localized Micropeptide, MP60, Promotes Hepatocellular Carcinoma Progression via the Epithelial-Mesenchymal Transition. Cancers, 17(17), 2932. https://doi.org/10.3390/cancers17172932
Vancouver
Li C, Hong X, Setrerrahmane S, Sun X, Zhang X, Xu H. A Novel Nuclear-Localized Micropeptide, MP60, Promotes Hepatocellular Carcinoma Progression via the Epithelial-Mesenchymal Transition. Cancers. 2025;17(17):2932. doi:10.3390/cancers17172932
BibTeX
@article{Li2025,
author = {Li, Chencheng and Hong, Xiu and Setrerrahmane, Sarra and Sun, Xiaoyi and Zhang, Xue and Xu, Hanmei},
title = {A Novel Nuclear-Localized Micropeptide, MP60, Promotes Hepatocellular Carcinoma Progression via the Epithelial-Mesenchymal Transition},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2932},
doi = {10.3390/cancers17172932}
}
EUVIMED